• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Bard seeks pelvic mesh trial delay over judge’s comments

Bard seeks pelvic mesh trial delay over judge’s comments

January 8, 2015 By Brad Perriello

Bard seeks mesh trial delay over judge's comments

C.R. Bard (NYSE:BCR) yesterday asked the federal judge overseeing thousands of lawsuits brought against it to delay a trial slated for next month, arguing that the judge’s comments during a hearing last month prejudiced the jury pool.

Judge Joseph Goodwin of the U.S. District Court for Southern West Virginia is supervising a multi-district litigation involving thousands of the lawsuits filed over Bard’s pelvic mesh devices for pelvic organ prolapse and stress urinary incontinence.

Last month, Goodwin’s comments urging Bard to settle the mesh lawsuits drew widespread publicity.

"I can’t imagine a corporation facing potentially billions of dollars in verdicts wouldn’t find it advisable to try to achieve a settlement for a much lesser sum," Goodwin said at the Dec. 9 hearing. "I base that billions of dollars business on some of the rather large verdicts that we’ve had.”

Bard and other makers of pelvic mesh products, designed to treat pelvic organ prolapse and stress urinary incontinence, are facing 10s of thousands of lawsuits in state and federal courts. In November a jury in West Virginia awarded 4 women $18.5 million for injuries they said were caused by Boston Scientific‘s (NYSE:BSX) Obtryx device for stress urinary incontinence, including $4 million for "gross negligence." That verdict came a week after a Miami jury awarded $26.7 million to 4 women implanted with the company’s Pinnacle device for pelvic organ prolapse. Those rulings and court losses by other mesh makers ought to spur Bard to settle the more than 12,400 such cases it’s facing, Goodwin said. Bard in October inked a settlement deal for some 500 of the cases that’s reportedly worth about $21 million.

"I find it to be a material fact that 5 different state forums have, on average, returned verdicts of over a million dollars per plaintiff," the judge said. "If I were a stockholder of any of these companies, I would be materially interested in the fact that there have been multiple million-dollar verdicts for individual plaintiffs."

Bard argued yesterday that the widespread coverage of Goodwin’s comments make it impossible to hold a fair trial as scheduled for February.

"Based on reports in the news media and by analysts, potential jurors could readily conclude that the court believes: (i) Bard is liable for plaintiffs’ alleged injuries; (ii) that presumptive liability should expose Bard to billions of dollars in damages; (iii) individual plaintiffs should recover substantial amounts, based upon multiple million-dollar verdicts; and (iv) Bard should settle all MDL cases," the company argued, according to court documents [italics theirs].

"That this is so demonstrates that the jury pool has quite likely been tainted," the company wrote. "Even if the court instructs jurors and potential jurors to ignore the media and avoid internet research, the effect of those instructions is only prospective. It cannot immunize the jury against the prejudicial information its members may have already seen. Only time may dissipate that taint."

Filed Under: Legal News, News Well Tagged With: C.R. Bard, Pelvic Mesh Lawsuits

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy